Solid Biosciences Balance Sheet Health
Financial Health criteria checks 6/6
Solid Biosciences has a total shareholder equity of $193.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $231.0M and $37.7M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$190.27m |
| Equity | US$193.25m |
| Total liabilities | US$37.74m |
| Total assets | US$230.98m |
Recent financial health updates
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth
Jul 26
We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Mar 17Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans
Oct 28We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Jul 13We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely
Mar 17Recent updates
We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth
Jul 26Buy Solid Biosciences: Unpacking Its Main Value Driver
Apr 10Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid
Jan 17Solid Biosciences to acquire gene therapy company AavantiBio
Sep 30Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results
Apr 30Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates
Apr 28We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Mar 17Solid Biosciences (NASDAQ:SLDB) Is In A Good Position To Deliver On Growth Plans
Oct 28We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate
Jul 13We're Hopeful That Solid Biosciences (NASDAQ:SLDB) Will Use Its Cash Wisely
Mar 17Soild Bio sinks 13% after Sarepta data misses goal
Jan 08Solid Biosciences launches $90M private placement
Dec 11Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data
Nov 10Financial Position Analysis
Short Term Liabilities: SLDB's short term assets ($197.6M) exceed its short term liabilities ($14.7M).
Long Term Liabilities: SLDB's short term assets ($197.6M) exceed its long term liabilities ($23.0M).
Debt to Equity History and Analysis
Debt Level: SLDB is debt free.
Reducing Debt: SLDB has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SLDB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SLDB has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 4% each year.